Evidence map›Paper›PMID 31983929›Full record

ArticleLung cancer management2020

Can tumor mutational burden determine the most effective treatment for lung cancer patients?

Shixiang Wang, Zaoke He, Xuan Wang, Huimin Li, Tao Wu, Xiaoqin Sun, Kai Wu, Xue-Song Liu

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shixiang WangSchool of Life Science & Technology, ShanghaiTech University, Shanghai 201203, China.ORCID https://orcid.org/0000-0001-9855-7357
Zaoke HeSchool of Life Science & Technology, ShanghaiTech University, Shanghai 201203, China.
Xuan WangSchool of Life Science & Technology, ShanghaiTech University, Shanghai 201203, China.
Huimin LiSchool of Life Science & Technology, ShanghaiTech University, Shanghai 201203, China.
Tao WuSchool of Life Science & Technology, ShanghaiTech University, Shanghai 201203, China.
Xiaoqin SunSchool of Life Science & Technology, ShanghaiTech University, Shanghai 201203, China.
Kai WuDepartment of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Xue-Song LiuSchool of Life Science & Technology, ShanghaiTech University, Shanghai 201203, China.ORCID https://orcid.org/0000-0002-7736-0077

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkercancer immunotherapyimmune checkpoint inhibitorlung cancerTMBtumor mutational burden

Identifiers

PMID31983929
PMCPMC6978725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.